Clinical Trial Update: Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment [Phase 1]

View source ↗

Summary

This completed Phase 1 study evaluated the pharmacokinetics and safety of Inaxaplin in participants with mild or moderate hepatic impairment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• Inaxaplin (inaxaplin)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Focal Segmental Glomerulosclerosis (FSGS) | Phase 1 | Status: COMPLETED